HomeBUSINESS
BUSINESS

Toyama Chemical Begins Patient Enrollment in Japan PIII Study of Avigan for SFTS
(Mar.13.2018)

Toyama Chemical, a group company of Fujifilm Holdings, said on March 12 that it has commenced patient enrollment in a PIII study of its RNA polymerase inhibitor Avigan (favipiravir) in Japan for ixodid tick-borne infectious disease, serious fever with thrombocytopenia syndrome (SFTS) ...
(LOG IN FOR FULL STORY)